Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000711934 | SCV000842345 | uncertain significance | not provided | 2018-04-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000711934 | SCV002225064 | uncertain significance | not provided | 2024-05-13 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 2118 of the HSPG2 protein (p.Arg2118His). This variant is present in population databases (rs144032875, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with HSPG2-related conditions. ClinVar contains an entry for this variant (Variation ID: 585998). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV000711934 | SCV003811913 | uncertain significance | not provided | 2019-07-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004026817 | SCV004884463 | uncertain significance | Inborn genetic diseases | 2023-01-23 | criteria provided, single submitter | clinical testing | The c.6353G>A (p.R2118H) alteration is located in exon 49 (coding exon 49) of the HSPG2 gene. This alteration results from a G to A substitution at nucleotide position 6353, causing the arginine (R) at amino acid position 2118 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |